News | May 13, 2025
Morepen Laboratories reports Q4 FY25 consolidated PAT at Rs. 20.31 Cr
The company has posted net profit of Rs. 118.01 crores for the Financial Year ended March 31, 2025
The company has posted net profit of Rs. 118.01 crores for the Financial Year ended March 31, 2025
The company has posted net profit of Rs.168.16 crores for the Financial Year ended March 31, 2025
The company has posted net loss of Rs. 17.97 crores for the Financial Year ended March 31, 2025
The company has posted net profit of Rs. 158.71 crores for the Financial Year ended March 31, 2025
The company has posted net profit of Rs.5.71 crores for the Financial Year ended March 31, 2025
For the financial year ended March 31, 2025, Thyrocare has reported total income of Rs.702.18 crores
The company delivered revenues of Rs. 5,554 crore, representing 10% growth in FY25
The new facility combines advanced technology, enhanced capacity, and holistic care, reaffirming HCG’s commitment to accessible, world-class oncology in Gujarat
DESTINY-Breast09 Phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2-positive metastatic patient population versus current 1st-line standard of care
Data highlight ambition to transform prevention and treatment for serious bacterial infections and develop novel preventative strategies for respiratory viral infections
Subscribe To Our Newsletter & Stay Updated
